Beat the Market the Zacks Way: DaVita, Block, Home Depot in Focus
https://www.zacks.com/stock/news/2210009/beat-the-market-the-zacks-way-davita-block-home-depot-in-focus?cid=CS-ZC-FT-analyst_blog|investment_ideas-2210009
Jan 15, 2024 - Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our key performance data from the past three months.
0
Reasons to Add Blueprint (BPMC) Stock to Your Portfolio Now
https://www.zacks.com/stock/news/2210923/reasons-to-add-blueprint-bpmc-stock-to-your-portfolio-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2210923
Jan 16, 2024 - Here, we discuss some reasons why investing in Blueprint (BPMC) stock now may turn out to be a more prudent move than ever.
0
Is ADC Therapeutics (ADCT) Outperforming Other Medical Stocks This Year?
https://www.zacks.com/stock/news/2212816/is-adc-therapeutics-adct-outperforming-other-medical-stocks-this-year?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_1-2212816
Jan 19, 2024 - Here is how ADC Therapeutics SA (ADCT) and CytomX Therapeutics (CTMX) have performed compared to their sector so far this year.
0
ADC Therapeutics (ADCT) Rises 43% in a Month: Here's Why
https://www.zacks.com/stock/news/2213007/adc-therapeutics-adct-rises-43-in-a-month-here-s-why?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2213007
Jan 19, 2024 - ADC Therapeutics (ADCT) surges after it provides business updates that highlight the company's progress with its pipeline. Multiple data readouts are expected throughout this year.
0
Mesoblast (MESO) Up on Rare Pediatric Disease Tag for Heart Drug
https://www.zacks.com/stock/news/2212927/mesoblast-meso-up-on-rare-pediatric-disease-tag-for-heart-drug?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2212927
Jan 19, 2024 - Mesoblast's (MESO) Revascor (rexlemestrocel-L) gets FDA's Rare Pediatric Disease designation for treating children with congenital heart disease. Shares rise in after-hours trading.
0
Alvotech (ALVO) Up on BLA Update for Two Biosimilar Candidates
https://www.zacks.com/stock/news/2213525/alvotech-alvo-up-on-bla-update-for-two-biosimilar-candidates?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2213525
Jan 22, 2024 - The FDA concludes the reinspection of Alvotech's (ALVO) facility in Iceland. The company believes that it may receive approval for biosimilar candidates, AVT02 and AVT04, in the United States. Stock rises.
0
Ionis' (IONS) Donidalorsen Meets Late-Stage HAE Study Goal
https://www.zacks.com/stock/news/2214493/ionis-ions-donidalorsen-meets-late-stage-hae-study-goal?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2214493
Jan 23, 2024 - Ionis (IONS) reports positive phase III study results, which show that treatment with donidalorsen achieved a statistically significant reduction in HAE attacks.
0
GSK Gears Up for Q1 Earnings: Here's What to Expect
https://www.zacks.com/stock/news/2260559/gsk-gears-up-for-q1-earnings-here-s-what-to-expect?cid=CS-ZC-FT-analyst_blog|earnings_article-2260559
Apr 23, 2024 - We expect GSK's specialty products like Arexvy, Cabenuva, Juluca, Dovato, Nucala, Trelegy Ellipta and Shingrix to drive first-quarter sales performance.
0